论文部分内容阅读
目的 探讨血清新喋呤水平与肺癌的关系及其临床意义。方法 采用酶联免疫吸附竞争抑制法检测了 3 2例健康献血员、43例肺癌患者的血清新喋呤水平。结果 初诊肺癌患者血清新喋呤水平为 ( 5 .7± 3 .4) μg/L ,显著高于正常对照组的 ( 1.5±0 .7) μg/L(P <0 .0 1)。除N2 期患者血清新喋呤水平较高以外 ,不同病期、不同病理类型的肺癌患者血清新喋呤水平无显著性差异。结论 肺癌患者存在异常的细胞免疫应答 ,检测血清新喋呤水平可作为判断肺癌患者细胞免疫功能的 1个客观指标。
Objective To investigate the relationship between serum neopterin and lung cancer and its clinical significance. Methods Enzyme linked immunosorbent assay (ELISA) was used to detect serum neopterin levels in 32 healthy blood donors and 43 lung cancer patients. Results The serum neopterin level of newly diagnosed lung cancer patients was (5. 7 ± 3. 4) μg / L, which was significantly higher than that of the control group (1.5 ± 0. 7) μg / L (P <0.01). In addition to high levels of serum neopterin N2 patients at different stages, different pathological types of lung cancer serum neopterin levels no significant difference. Conclusions Abnormal cellular immune response exists in patients with lung cancer. Detection of serum neopterin level can be used as an objective indicator of cellular immune function in patients with lung cancer.